This inventor holds 1 USPTO granted patent. Top assignee: Rhodia Chimie. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: Frédéric Mauger: Innovator in Pharmaceutical Compositions
Introduction
Frédéric Mauger is a notable inventor based in Changy, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of sustained-release tablet formulations. His innovative work has led to the creation of a unique pharmaceutical composition that enhances the delivery of active ingredients.
Latest Patents
Frédéric Mauger holds a patent for "Pharmaceutical compositions in the form of sustained-release tablets based on high molecular weight polysaccharide granules." This invention relates to a delayed-release pharmaceutical composition that is prepared by direct tableting. The composition consists of at least one active principle and a matrix that provides the delayed-release effect. The matrix is characterized by its inclusion of pregranulated polysaccharides of high molecular weight, which can be of synthetic or natural origin. This innovative approach allows for improved therapeutic outcomes in patients.
Career Highlights
Mauger is associated with Rhodia Chimie, a company known for its advancements in chemical and pharmaceutical products. His work at Rhodia Chimie has allowed him to focus on developing innovative solutions that address the needs of the pharmaceutical industry. His expertise in formulating sustained-release tablets has positioned him as a key player in this specialized field.
Collaborations
Frédéric Mauger has collaborated with notable colleagues such as Jean-Pierre Collaueri and Guillaume Conrath. These collaborations have fostered an environment of innovation and have contributed to the successful development of new pharmaceutical technologies.
Conclusion
Frédéric Mauger's contributions to the field of pharmaceuticals, particularly through his patented work on sustained-release tablets, highlight his role as an innovator. His collaborations and career at Rhodia Chimie further emphasize his commitment to advancing pharmaceutical science. His work continues to impact the industry positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile